UNSPSC 51162305: Acetaminophen/caffeine/chlorpheniramine/phenylephrine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162305 Acetaminophen/caffeine/chlorpheniramine/phenylephrine/pyrilamine is a Commodity code that nominally describes a specific combination pharmaceutical product, but recent state and local solicitations tagged under this code are actually procuring a much broader range of generic multi-source pharmaceuticals and over-the-counter products, including naloxone and drug deactivation systems. The actual buying reflects the way state and local health and human services agencies source pharmaceutical inventories through standing contracts with manufacturers and wholesalers rather than individual drug formulations. Issuing bodies include county public health departments, state agencies administering cooperative purchasing vehicles, and networks of participating state and local facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, solicits manufacturers on behalf of multiple participating states. Individual counties—such as Seminole County, Florida—also issue their own pharmaceutical and health-supply procurement notices independently.

Geographic activity centers on the Upper Midwest and Southeast, with solicitations from Minnesota (MMCAP) and Florida. The two most visible recent opportunities are MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802), due March 26, 2026, seeking manufacturers to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with awards effective July 1, 2026; and Seminole County's June 2026 IFB for naloxone and drug deactivation systems (IFB60459723LAS), requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, closed July 26, 2023. Both opportunities require full compliance with FDA and Good Manufacturing Practice standards, detailed product and pricing submissions through electronic systems, and maintenance of significant insurance coverage. The MMCAP procurement weights price competitiveness at 75 percent and evaluates vendors on NDC-level product availability, EDI capability, and willingness to accept a 3 percent administrative fee; neither opportunity specifies set-aside designations.